Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback